Jump to content

Simtuzumab

From Wikipedia, the free encyclopedia
Simtuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetLOXL2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6558H10134N1736O2037S50
Molar mass147492.33 g·mol−1

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  3. ^ "Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis". Gilead. 5 January 2016.